ICD   PCS   Disclaimer
PCS-2023 Procedure Codes Overview
PCS-2023 > X > XW > XW0 > XW03
XW0

Anatomical Regions, Introduction

Info:
Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
XW03

Introduction, Peripheral Vein

XW033
Percutaneous
XW0330
Brexanolone
XW03306
Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03308
Introduction of Spesolimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0332
Nerinitide
XW03326
Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0333
Durvalumab Antineoplastic
XW03336
Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW0335
Narsoplimab Monoclonal Antibody
XW03357
Introduction of Narsoplimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03358
Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0336
Lefamulin Anti-infective
XW03366
Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03367
Introduction of Terlipressin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03368
Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0337
Coagulation Factor Xa, Inactivated
XW03372
Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
XW03377
Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03378
Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0338
Lurbinectedin
XW03387
Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW03388
Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW0339
Ceftolozane/Tazobactam Anti-infective
XW03396
Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW03398
Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
XW033A
Cefiderocol Anti-infective
XW033A6
Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033A7
Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033B
Cytarabine and Daunorubicin Liposome Antineoplastic
XW033B3
Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033B6
Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033B7
Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033C
Eculizumab
XW033C6
Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033C7
Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033D
Atezolizumab Antineoplastic
XW033D6
Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033E
Remdesivir Anti-infective
XW033E5
Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033E6
Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033F
Other New Technology Therapeutic Substance
XW033F3
Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3
XW033F5
Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F6
Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G
Plazomicin Anti-infective
XW033G4
Introduction of Plazomicin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW033G5
Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G6
Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033G7
Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033H
Synthetic Human Angiotensin II
XW033H4
Introduction of Synthetic Human Angiotensin II into Peripheral Vein, Percutaneous Approach, New Technology Group 4
XW033H5
Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H6
Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033H7
Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033J
Tisagenlecleucel Immunotherapy
XW033J7
Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033K
Fosfomycin Anti-infective
XW033K5
Introduction of Fosfomycin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033K7
Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033L
CD24Fc Immunomodulator
XW033L6
Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6
XW033L7
Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033M
Brexucabtagene Autoleucel Immunotherapy
XW033M7
Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033N
Meropenem-vaborbactam Anti-infective
XW033N5
Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033N7
Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
XW033Q
Tagraxofusp-erzs Antineoplastic
XW033Q5
Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033S
Iobenguane I-131 Antineoplastic
XW033S5
Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033U
Imipenem-cilastatin-relebactam Anti-infective
XW033U5
Introduction of Imipenem-cilastatin-relebactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033W
Caplacizumab
XW033W5
Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

 

ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine